Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study - Scorecard - MDSpire

Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study

  • By

  • Ryan T Demmer

  • Chaoqi Wu

  • John S Kim

  • Yifei Sun

  • Pallavi Balte

  • Mary Cushman

  • Rebekah Boyle

  • Russell P Tracy

  • Linda M Styer

  • Taison D Bell

  • Michaela R Anderson

  • Norrina B Allen

  • Pamela J Schreiner

  • Russell Bowler

  • David A Schwartz

  • Joyce S Lee

  • Vanessa Xanthakis

  • Jean M Rock

  • Rachel Bievenue

  • Amber Pirzada

  • Margaret Doyle

  • Elizabeth A Regan

  • Barry J Make

  • Alka M Kanaya

  • Namratha R Kandula

  • Sally E Wenzel

  • Josef Coresh

  • Carmen R Isasi

  • Laura M Raffield

  • Mitchell S V Elkind

  • Virginia J Howard

  • Victor E Ortega

  • Prescott Woodruff

  • Shelley A Cole

  • Joel M Henderson

  • Nicholas J Mantis

  • Elizabeth C Oelsner

  • March 20, 2025

  • 0 min

Share

Clinical Scorecard: Factors Influencing Anti-Nucleocapsid Antibody Responses to SARS-CoV-2 in Previously Infected Adults in the US: Insights from the C4R Study

At a Glance

CategoryDetail
ConditionSARS-CoV-2 infection and adaptive immune response
Key MechanismsAnti-nucleocapsid (N) antibody response generated by natural infection, not vaccination; dynamics of antibody waning over time
Target PopulationPreviously SARS-CoV-2 infected US adults, including diverse racial/ethnic groups and older adults
Care SettingClinical practice, serosurveillance, and research settings

Key Highlights

  • Anti-nucleocapsid antibody reactivity peaks at 69% by 4 months post-infection and wanes to 44% at ≥12 months.
  • Higher anti-N antibody response associated with older age, Hispanic or American Indian/Alaskan Native ethnicity, lower income and education, former smoking, and higher anti-spike antibody levels.
  • Vaccination and Asian race associated with lower anti-nucleocapsid antibody reactivity; cardiometabolic comorbidities and vaccine manufacturer not associated.

Guideline-Based Recommendations

Diagnosis

  • Use anti-nucleocapsid antibody testing to identify prior natural SARS-CoV-2 infection, recognizing waning antibody levels over time.
  • Consider demographic and clinical factors that influence anti-N antibody detection to reduce misclassification.

Management

  • Account for variable anti-N antibody responses when assessing infection history in clinical and research contexts.
  • Incorporate vaccination status and time since infection when interpreting serological results.

Monitoring & Follow-up

  • Monitor anti-nucleocapsid antibody levels longitudinally to understand immune response durability.
  • Use serosurveillance data to identify populations with differential antibody responses for targeted interventions.

Risks

  • Potential misclassification of prior infection status due to waning or absent anti-N antibody response, especially in vaccinated individuals or certain racial groups.
  • Selection bias in studies of post-acute sequelae if anti-N antibody response variability is not accounted for.

Patient & Prescribing Data

Adults with prior SARS-CoV-2 infection across diverse racial/ethnic and socioeconomic backgrounds in the US.

Vaccination after infection lowers anti-nucleocapsid antibody reactivity; anti-N antibody levels correlate with anti-spike antibody levels but are not influenced by vaccine manufacturer or cardiometabolic comorbidities.

Clinical Best Practices

  • Interpret anti-nucleocapsid antibody test results in the context of time since infection, vaccination status, and patient demographics.
  • Use combined serological markers (anti-spike and anti-nucleocapsid antibodies) for more accurate assessment of infection and immune status.
  • Recognize limitations of anti-N antibody testing in older adults and certain racial/ethnic groups to avoid diagnostic errors.
  • Incorporate detailed patient history including smoking status and socioeconomic factors when evaluating antibody responses.

References

Original Source(s)

Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study

  • by Ryan T Demmer, Chaoqi Wu, John S Kim, Yifei Sun, Pallavi Balte, Mary Cushman, Rebekah Boyle, Russell P Tracy, Linda M Styer, Taison D Bell, Michaela R Anderson, Norrina B Allen, Pamela J Schreiner, Russell Bowler, David A Schwartz, Joyce S Lee, Vanessa Xanthakis, Jean M Rock, Rachel Bievenue, Amber Pirzada, Margaret Doyle, Elizabeth A Regan, Barry J Make, Alka M Kanaya, Namratha R Kandula, Sally E Wenzel, Josef Coresh, Carmen R Isasi, Laura M Raffield, Mitchell S V Elkind, Virginia J Howard, Victor E Ortega, Prescott Woodruff, Shelley A Cole, Joel M Henderson, Nicholas J Mantis, Elizabeth C Oelsner

  • March 20, 2025

Related Content

MEK1/2 inhibitor ATR-002 reshapes host transcriptome and modulates immune regulatory genes in SARS-CoV-2 infection

Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care

High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis